2024
Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case–Control Analysis Within the EPIC Study
Almanza-Aguilera E, Martínez-Huélamo M, López-Hernández Y, Guiñón-Fort D, Guadall A, Cruz M, Perez-Cornago A, Rostgaard-Hansen A, Tjønneland A, Dahm C, Katzke V, Schulze M, Masala G, Agnoli C, Tumino R, Ricceri F, Lasheras C, Crous-Bou M, Sánchez M, Aizpurua-Atxega A, Guevara M, Tsilidis K, Chatziioannou A, Weiderpass E, Travis R, Wishart D, Andrés-Lacueva C, Zamora-Ros R. Prediagnostic Plasma Nutrimetabolomics and Prostate Cancer Risk: A Nested Case–Control Analysis Within the EPIC Study. Cancers 2024, 16: 4116. PMID: 39682302, PMCID: PMC11639937, DOI: 10.3390/cancers16234116.Peer-Reviewed Original ResearchProstate cancer riskProstate cancerPCa riskBiomarkers of food intakeMultivariate conditional logistic regression analysisNested case-control analysisAdvanced PCa riskFatal prostate cancerCancer and NutritionConditional logistic regression analysisOverall PCa riskEuropean Prospective InvestigationMetabolite concentrationsCase-control analysisCase-control pairsLogistic regression analysisClinically relevant tumor subtypesMetabolomics approachTumor subtypesProspective InvestigationClinical subtypesCancer riskFood intakeMetabolic alterationsEPIC studyIntegrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma
Han S, Camp S, Chu H, Collins R, Gillani R, Park J, Bakouny Z, Ricker C, Reardon B, Moore N, Kofman E, Labaki C, Braun D, Choueiri T, AlDubayan S, Van Allen E. Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma. European Urology Open Science 2024, 62: 107-122. PMID: 38496821, PMCID: PMC10940785, DOI: 10.1016/j.euros.2024.02.006.Peer-Reviewed Original ResearchCopy number variantsGermline pathogenic variantsCryptic splice variantsNon-clear cell renal cell carcinomaCell renal cell carcinomaRare inherited mutationsRenal cell carcinomaPathogenic variantsSomatic eventsPopulation stratificationRisk of kidney cancerAge of cancer onsetGermline copy number variantsSplice variantsBurden of pathogenic variantsCell carcinomaEstimation of genetic riskRenal cell carcinoma riskRCC patientsCancer-free controlsCase-control analysisCase-control studyRenal cell carcinoma patientsClear cell renal cell carcinomaGermline rare variants
2023
2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023
DeCuir J, Zhu Y, Gaglani M, Ginde A, Mohr N, Gibbs K, Hager D, Frosch A, Mohamed A, Johnson N, Steingrub J, Peltan I, Martin E, Bender W, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Womack K, Swan S, McMorrow M, Self W, Surie D. 2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.153. PMCID: PMC10677158, DOI: 10.1093/ofid/ofad500.153.Peer-Reviewed Original ResearchCOVID-19-associated hospitalizationRelative vaccine effectivenessVaccine effectivenessBooster doseSARS-CoV-2Hospitalized adultsIllness onsetDays of receiptCOVID-19 vaccination seriesCOVID-19-like illnessAdditional booster dosesAsahi Kasei PharmaMRNA vaccine effectivenessMultivariable logistic regressionHuman Services (HHS) regionsCase-control analysisUnvaccinated patientsVaccination seriesBooster dosesImmunization PracticesMRNA vaccinationAdults AgedRespiratory virusesAntigen testAdmission dateCirculating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 ☆
Parsons H, Blewett T, Chu X, Sridhar S, Santos K, Xiong K, Abramson V, Patel A, Cheng J, Brufsky A, Rhoades J, Force J, Liu R, Traina T, Carey L, Rimawi M, Miller K, Stearns V, Specht J, Falkson C, Burstein H, Wolff A, Winer E, Tayob N, Krop I, Makrigiorgos G, Golub T, Mayer E, Adalsteinsson V. Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030 ☆. Annals Of Oncology 2023, 34: 899-906. PMID: 37597579, PMCID: PMC10898256, DOI: 10.1016/j.annonc.2023.08.004.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerResidual cancer burdenNeoadjuvant chemotherapyCancer burdenBreast cancerWeek 3Additional neoadjuvant chemotherapyPlasma samplesCase-control analysisCtDNA clearanceCtDNA positivityNeoadjuvant paclitaxelDisease recurrenceProspective studyWeek 12RCB 0CtDNA assaysPatientsSufficient tissueChemotherapyTumor fractionTumor DNARCB-3RespondersAdditional studiesAMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles
Li H, Seifer D, Tal R. AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles. Reproductive Biology And Endocrinology 2023, 21: 19. PMID: 36739415, PMCID: PMC9898926, DOI: 10.1186/s12958-023-01066-w.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneNumber of embryosEuploid embryosLive birthsOocyte qualityAge groupsSignificant independent predictorsCase-control analysisSART CORS databasePreimplantation genetic testingAMH levelsIVF cyclesIndependent predictorsIVF outcomesOocyte yieldNormal embryosPredictive roleGenetic testingFinal analysisBirthAgeIVFSubset of cyclesHormonePGT
2022
Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis
Lind M, Robertson A, Silva J, Warner F, Coppi A, Price N, Duckwall C, Sosensky P, Di Giuseppe E, Borg R, Fofana M, Ranzani O, Dean N, Andrews J, Croda J, Iwasaki A, Cummings D, Ko A, Hitchings M, Schulz W. Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case–control analysis. PLOS Medicine 2022, 19: e1004136. PMID: 36454733, PMCID: PMC9714718, DOI: 10.1371/journal.pmed.1004136.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionBooster vaccinationPrior infectionOmicron infectionPrimary vaccinationMRNA vaccinationOdds ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionPrior SARS-CoV-2 infectionTest-negative case-control analysisYale New Haven Health SystemTest-negative case-control studyCOVID-19 mRNA vaccinationSyndrome coronavirus 2 infectionOmicron variant infectionPrior infection statusCoronavirus 2 infectionCase-control studyCase-control analysisOdds of infectionRisk of infectionRace/ethnicityBooster dosesDate of testOdds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Internal Medicine 2022, 182: 179-184. PMID: 34846533, PMCID: PMC8634151, DOI: 10.1001/jamainternmed.2021.7382.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Maccabi Healthcare ServicesBooster doseBNT162b2 vaccineMRNA vaccinesPositive SARS-CoV-2 polymerase chain reaction testSARS-CoV-2 polymerase chain reaction testPreliminary retrospective case–control studyRetrospective case-control studyPositive PCR test resultsBNT162b2 mRNA vaccineVaccine-derived protectionTest-negative designDuration of immunityCase-control studyPolymerase chain reaction testEstimated odds ratioHealthcare servicesCase-control analysisPCR test resultsPositive test resultsChain reaction testCase-control designTesting PositiveOdds ratio
2021
Genetic and Epidemiologic Analyses of an Outbreak of Pneumocystis jirovecii Pneumonia Among Kidney Transplant Recipients in the United States
Azar MM, Cohen E, Ma L, Cissé OH, Gan G, Deng Y, Belfield K, Asch W, Grant M, Gleeson S, Koff A, Gaston DC, Topal J, Curran S, Kulkarni S, Kovacs JA, Malinis M. Genetic and Epidemiologic Analyses of an Outbreak of Pneumocystis jirovecii Pneumonia Among Kidney Transplant Recipients in the United States. Clinical Infectious Diseases 2021, 74: 639-647. PMID: 34017984, PMCID: PMC9012955, DOI: 10.1093/cid/ciab474.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsCases of PCPPneumocystis pneumoniaClinic visitsRisk factorsClinic exposureLow absolute lymphocyte countRisk of PCPAbsolute lymphocyte countFrequent clinic visitsPneumocystis jirovecii pneumoniaStrong risk factorNon-white raceCase-control analysisBelatacept groupMonthly infusionsTransplant recipientsBaseline characteristicsJirovecii pneumoniaLymphocyte countMultilocus sequence typingInterhuman transmissionRespiratory specimensUnivariate analysisEpidemiologic dataCOVID-19 Transmission in US Child Care Programs
Gilliam WS, Malik AA, Shafiq M, Klotz M, Reyes C, Humphries JE, Murray T, Elharake JA, Wilkinson D, Omer SB. COVID-19 Transmission in US Child Care Programs. Pediatrics 2021, 147: e2020031971. PMID: 33055228, DOI: 10.1542/peds.2020-031971.Peer-Reviewed Original ResearchConceptsCare programCOVID-19 transmissionCare providersCOVID-19Child care programsChild care providersPropensity score-matched case-control analysisCOVID-19 outcomesLogistic regression analysisCase-control analysisUS COVID-19 pandemicChild carePotential confoundersElevated riskHome-based providersCareUS pandemicRegression analysisCOVID-19 pandemicDegree of exposureExposureMonthsOutcomesEarly monthsProviders
2020
COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis
Boddington N, Charlett A, Elgohari S, Walker J, McDonald H, Byers C, Coughlan L, Vilaplana T, Whillock R, Sinnathamby M, Panagiotopoulos N, Letley L, MacDonald P, Vivancos R, Edeghere O, Shingleton J, Bennett E, Grint D, Strongman H, Mansfield K, Rentsch C, Minassian C, Douglas I, Mathur R, Peppa M, Cottrell S, McMenamin J, Zambon M, Ramsay M, Dabrera G, Saliba V, Bernal J. COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis. Bulletin Of The World Health Organization 2020, 99: 178-189. PMID: 33716340, PMCID: PMC7941108, DOI: 10.2471/blt.20.265603.Peer-Reviewed Original ResearchConceptsProportion of COVID-19 casesPredictive value of symptomsTraining public health professionalsHealth-care seeking behaviorOccurrence of feverCase-control analysisCourse of diseaseSpecificity of symptomsShortness of breathPublic health professionalsProportion of childrenClinical presentationClinical characteristicsExposure to infectionRespiratory infectionsCases of coronavirus disease 2019Household contactsHealth professionalsBurden of COVID-19Predictive valueCase definitionCoronavirus disease 2019COVID-19 casesControl groupFever
2019
Genetic association analysis of 5‐HTR2A gene variants in eating disorders in a Mexican population
Genis‐Mendoza A, Ruiz‐Ramos D, López‐Narvaez M, Tovilla‐Zárate C, García A, Meda G, Martinez‐Magaña J, González‐Castro T, Juárez‐Rojop I, Nicolini H. Genetic association analysis of 5‐HTR2A gene variants in eating disorders in a Mexican population. Brain And Behavior 2019, 9: e01286. PMID: 31199591, PMCID: PMC6625474, DOI: 10.1002/brb3.1286.Peer-Reviewed Original ResearchRamucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts).
De Wit R, Powles T, Castellano D, Necchi A, Lee J, Van Der Heijden M, Matsubara N, Bamias A, Flechon A, Sternberg C, Drakaki A, Yu E, Hamid O, Zimmermann A, Gao L, Long A, Walgren R, Bell-McGuinn K, Petrylak D. Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts). Journal Of Clinical Oncology 2019, 37: 353-353. DOI: 10.1200/jco.2019.37.7_suppl.353.Peer-Reviewed Original ResearchRandomized phase III trialFavorable prognostic featuresMultivariate Cox regressionPhase III trialsPoor prognostic factorUrothelial carcinoma patientsPopulation pharmacokinetic analysisCase-control analysisExposure-response relationshipHigh exposureWarrants further explorationFirst doseIII trialsPrognostic factorsCarcinoma patientsPrognostic featuresCox regressionDiscontinuation criteriaAcceptable safetyLonger survivalRisk factorsRam exposureORR benefitPharmacokinetic analysisDocetaxel
2017
Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis
Lekavich CL, Barksdale DJ, Wu JR, Neelon V, Crandell J, Velazquez EJ. Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis. Journal Of Cardiac Failure 2017, 23: 659-665. PMID: 28716687, PMCID: PMC5585062, DOI: 10.1016/j.cardfail.2017.07.395.Peer-Reviewed Original ResearchConceptsVentricular-arterial couplingControl groupEchocardiographic markersEjection fractionHeart failureControl subjectsCase groupHigher oddsConditional logistic regression analysisMatched Case-Control AnalysisDate of echocardiographyIncident heart failureConditional logistic regressionLogistic regression analysisCase-control analysisTimes higher oddsIncident HFpEFAtrial diameterTransthoracic echocardiogramProspective studyStudy cohortMortality implicationsUse of EESHFpEFVentricular elastance
2014
Acoustic neuroma: potential risk factors and audiometric surveillance in the aluminium industry
Taiwo O, Galusha D, Tessier-Sherman B, Kirsche S, Cantley L, Slade MD, Cullen MR, Donoghue AM. Acoustic neuroma: potential risk factors and audiometric surveillance in the aluminium industry. Occupational And Environmental Medicine 2014, 71: 624. PMID: 25015928, PMCID: PMC4145445, DOI: 10.1136/oemed-2014-102094.Peer-Reviewed Original ResearchConceptsHearing conservation programAcoustic neuromaRisk factorsMultivariate analysisPossible occupational risk factorsSignificant risk factorsOccupational risk factorsAluminum production workersPotential risk factorsCase-control analysisInsurance claims dataUndiagnosed tumorsIncidental detectionPopulation of workersHearing lossAudiometric surveillanceClaims dataMedical surveillanceDetection biasBivariate analysisNoise doseThe KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905
Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-Variant and miRNA Expression in RTOG Endometrial Cancer Clinical Trials 9708 and 9905. PLOS ONE 2014, 9: e94167. PMID: 24732316, PMCID: PMC3986055, DOI: 10.1371/journal.pone.0094167.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskType 2 endometrial cancerEndometrial cancerKRAS-variantCancer riskLymphovascular invasionSurvival outcomesTumor biologyType 1 endometrial cancerEndometrial cancer trialsOverall survival rateMiRNA expressionAge-matched controlsCase-control analysisFunctional germline variantsClinical characteristicsPatient ageTumor characteristicsCancer trialsTumor specimensSurvival rateType 1Germline variantsMiRNA expression levelsCancer
2011
Testing Gene-Environment Interaction in Large-Scale Case-Control Association Studies: Possible Choices and Comparisons
Mukherjee B, Ahn J, Gruber S, Chatterjee N. Testing Gene-Environment Interaction in Large-Scale Case-Control Association Studies: Possible Choices and Comparisons. American Journal Of Epidemiology 2011, 175: 177-190. PMID: 22199027, PMCID: PMC3286201, DOI: 10.1093/aje/kwr367.Peer-Reviewed Original ResearchConceptsGene-environment independenceGene-environment interactionsCase-only methodTesting gene-environment interactionsCase-control testsExposure under studyCase-control association studyUnderlying populationCase-control methodCase-control analysisFraction of markersType I error propertiesGenome-wide scanClass of proceduresAssociation studiesData-adaptive wayComparative simulation studyLarge-scale studiesEmpirical-BayesIndependence assumptionFalse positivesPopulationReplication strategyHybrid methodIndependenceAsthma exacerbation and proximity of residence to major roads: a population-based matched case-control study among the pediatric Medicaid population in Detroit, Michigan
Li S, Batterman S, Wasilevich E, Elasaad H, Wahl R, Mukherjee B. Asthma exacerbation and proximity of residence to major roads: a population-based matched case-control study among the pediatric Medicaid population in Detroit, Michigan. Environmental Health 2011, 10: 34. PMID: 21513554, PMCID: PMC3224543, DOI: 10.1186/1476-069x-10-34.Peer-Reviewed Original ResearchConceptsConditional logistic regressionPopulation-based matched case-control studyPediatric Medicaid populationCase-control studyMedicaid populationProximity of residenceLogistic regressionConditional logistic regression modelsElevated risk of asthmaRisk of asthmaEmergency department visitsCase-control analysisLogistic regression modelsHigh-risk populationTraffic-related pollutantsAsthma outcomesDepartment visitsAsthma eventsAsthma claimAsthma-related eventsAsthma casesEcological biasOdds ratioInvestigate associationsMethodThis studyRare variants in the ATMgene and risk of breast cancer
Goldgar D, Healey S, Dowty J, Da Silva L, Chen X, Spurdle A, Terry M, Daly M, Buys S, Southey M, Andrulis I, John E, BCFR, kConFab, Khanna K, Hopper J, Oefner P, Lakhani S, Chenevix-Trench G. Rare variants in the ATMgene and risk of breast cancer. Breast Cancer Research 2011, 13: r73. PMID: 21787400, PMCID: PMC3236337, DOI: 10.1186/bcr2919.Peer-Reviewed Original ResearchMeSH KeywordsAtaxia Telangiectasia Mutated ProteinsBreast NeoplasmsCase-Control StudiesCell Cycle ProteinsDNA-Binding ProteinsFemaleGenetic Predisposition to DiseaseGenetic VariationHumansLogistic ModelsLoss of HeterozygosityMiddle AgedMutation, MissenseProtein Serine-Threonine KinasesTumor Suppressor ProteinsWhite PeopleConceptsRisk of breast cancerRare sequence variantsLoss of heterozygositySequence variantsIncreased risk of breast cancerBreast cancerAssociated with increased breast cancerATM variantsCase-control family studyHazard ratioModified segregation analysisCases of breast cancerRisk of BCRare ATM variantsIncreased riskConditional logistic regressionATM geneAnalysis of loss of heterozygosityCellular response to DNA double-strand breaksResponse to DNA double-strand breaksFamily-based analysisCase-control analysisDNA damage-response pathwayATM c.Magnitude of risk
2010
A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancerA Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01
Cree BA, Rioux JD, McCauley JL, Gourraud PA, Goyette P, McElroy J, De Jager P, Santaniello A, Vyse TJ, Gregersen PK, Mirel D, Hafler DA, Haines JL, Pericak-Vance MA, Compston A, Sawcer SJ, Oksenberg JR, Hauser SL, , . A Major Histocompatibility Class I Locus Contributes to Multiple Sclerosis Susceptibility Independently from HLA-DRB1*15:01. PLOS ONE 2010, 5: e11296. PMID: 20593013, PMCID: PMC2892470, DOI: 10.1371/journal.pone.0011296.Peer-Reviewed Original ResearchConceptsCase-control analysisMS susceptibilityMultiple sclerosisSingle nucleotide polymorphismsClass IMS susceptibility allelesMultiple sclerosis susceptibilityMajor histocompatibility class ICochran-Armitage trend testLogistic regression modelingHLA-G geneMHC class IReplication datasetDiscovery datasetHistocompatibility class IArmitage trend testHLASignificant associationClass IIGenetic susceptibilityMajor histocompatibility complex (MHC) genesRegression modelingSusceptibility allelesP-valueMHC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply